LIHT CANNABIS Forum: Community User: moojoo

@Boris: kann man drehen und wenden. Ist ne 1 Drittel-Verwässerung. Wenn ich das allerdings richtig in Erinnerung habe, übernimmt FSM die Kosten für die 10 x 10000sqft-Gebäude.

@Boris Dein Bier

Gut ist, dass die Kanadier nun auf das Unternehmen aufmerksam werden. Ich glaub das sind da alle Patrioten. Kanada und USA mögen sich ja nicht.

heißt das jetzt einsteigen oder nicht?

Kann man es auf deutsch Posten bitte. Danke

Ich verstehe Bahnhof

Mal schauen, was Canada daraus macht. Bid ist bei 0.29 CAD

Ist auch das aktuellste,daraufhin Aussetzung auf Wunsch des Unternehmens

VODIS PHARMACEUTICALS Gucken...

Habs jetzt auf Market wach gefunden. Man, wie enttäuschend.

@Domdomp Ist auf Stockwatch :-)

Ich glaube ich bin immer der letzte, der die News per Mail bekommt. :-) Danke Micha

@RnD: auf jeden Fall wäre das ein Grund. Schick mal n Link. Hab nix dazu gefunden.

KELOWNA, BC, Sept. 26, 2018 /PRNewswire/ - Marapharm Ventures Inc. (CSE: MDM) (OTCQX: MRPHF) (FSE: 2M0) ("Marapharm" or the "Company") is very pleased to announce, further to its news releases dated June 25 and August 21, 2018, the Company has completed its due diligence and has completed the acquisition (the "Acquisition") of all outstanding securities of Full Spectrum Medicinal Inc. ("FSM"). 10 fully-funded 10,000 sq. ft. engineered bio-secure facilities, will be constructed in two phases, maximizing our potential of a 100,000 sq. ft. ACMPR licence, once approved by Health Canada. FSM's organic cultivation methods, stand-alone proprietary technologies and supplemental power are intended to reduce our carbon footprint, cost of production and improve profitability.  We will benefit by setting new industry standards for cultivating premium cannabis products on a commercial scale. Ground preparation is now complete and delivery of our first facility is on schedule. The Acquisition On September 25, 2018, the Company signed the Definitive Agreement and has completed the Acquisition pursuant to a share exchange agreement made effective as of September 25, 2018 (the "Acquisition Agreement") among the Company, FSM and the shareholders of FSM (the "Selling Shareholders"), whereby the Company issued a total of 88,182,102 common shares of the Company, at a deemed price of $0.31 per share to the Selling Shareholders in exchange for all of the outstanding common shares of FSM. These shares are subject to an eighteen (18) month release schedule with twenty-five (25%) percent released on closing and twenty-five (25%) percent released every six (6) months thereafter.  Following the completion of the Acquisition, FSM is now a wholly-owned subsidiary of the Company. As part of the Acquisition, the Company issued 9,945,000 common share purchase warrants with an exercise price of $0.20c in exchange for cancelled FSM common share purchase warrants. A finder's fee in connection with the Acquisition was paid to a group of finders in the amount of 4,513,944 common shares on the Company at a deemed price of $0.205 per share. The Acquisition Agreement supersedes the operating agreement with FSM as previously disclosed in the Company's August 21, 2018 news release. Debenture Financing  The Company is pleased to announce that it intends to complete a non-brokered private placement of unsecured convertible debentures (the "Private Placement") in the principle amount of up to C$1,500,000 (the "Debenture") convertible debenture of the Company (the "Debenture") having an aggregate principal amount set forth below (the "Principal Amount") and bearing interest at a rate of 10% per annum payable at maturity, maturing on September 30, 2019.  The Debenture is convertible into common shares of the Company (the "Shares") at $0.20c per share with a $0.50c warrant exercisable for one year. On conversion, the Subscriber will receive any accrued and unpaid interest in cash.  The Debenture will be subject to a certificate, the form of which will be approved by the Company. Closing of the Private Placement is subject to all necessary regulatory and stock exchange approvals and execution of final documentation.  All securities issued in connection with the Private Placement will be subject to a four-month hold period from the date of issue under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. ABOUT MARAPHARM VENTURES INC. www.marapharm.com Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.  In preparation for the federal government's legalization of non-medical cannabis in October 2018, British Columbia has made a number of decisions about what our provincial regulatory framework will look like. 

Die FSM- Übernahme ist heute in den News. Aber wirklich ein Grund für Handelsstopp ist es auch nicht. In Kanada ist der Preis auch hoch gegangen vor dem Stopp.

Wäre ein Ansatz oder